Point72 Asset Management
NBIX icon

Point72 Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Point72 Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-837,426
Closed -$115M – 2251
2024
Q1 		$115M Sell
837,426
-554,544
-40% -$75.7M 0.28% 71
2023
Q4 		$183M Sell
1,391,970
-1,186,158
-46% -$137M 0.44% 25
2023
Q3 		$290M Buy
2,578,128
+2,466,770
+2,215% +$260M 0.85% 9
2023
Q2 		$10.5M Buy
+111,358
New +$10.9M 0.03% 569
2022
Q3 		– Sell
-665,300
Closed -$64.9M – 1626
2022
Q2 		$64.9M Buy
665,300
+87,402
+15% +$8.07M 0.27% 85
2022
Q1 		$54.2M Buy
577,898
+50,124
+9% +$4.25M 0.22% 135
2021
Q4 		$45M Buy
527,774
+378,826
+254% +$34.8M 0.18% 154
2021
Q3 		$14.3M Buy
+148,948
New +$14.1M 0.06% 401
2021
Q1 		– Sell
-22,679
Closed -$2.17M – 1107
2020
Q4 		$2.17M Buy
+22,679
New +$2.19M 0.01% 719
2020
Q2 		– Sell
-18,124
Closed -$1.57M – 944
2020
Q1 		$1.57M Sell
18,124
-41,879
-70% -$4.1M 0.01% 530
2019
Q4 		$6.45M Buy
60,003
+30,459
+103% +$3.19M 0.03% 460
2019
Q3 		$2.66M Sell
29,544
-1,095,140
-97% -$102M 0.02% 555
2019
Q2 		$95M Buy
1,124,684
+735,992
+189% +$60.4M 0.5% 47
2019
Q1 		$34.2M Buy
+388,692
New +$32.5M 0.16% 165
2018
Q4 		– Sell
-65,000
Closed -$7.99M – 1131
2018
Q3 		$7.99M Sell
65,000
-830,900
-93% -$94.3M 0.03% 498
2018
Q2 		$88M Buy
895,900
+820,900
+1,095% +$73.5M 0.35% 70
2018
Q1 		$6.22M Buy
+75,000
New +$6.33M 0.03% 528
2017
Q4 		– Sell
-276,322
Closed -$16.9M – 1021
2017
Q3 		$16.9M Sell
276,322
-310,678
-53% -$16.4M 0.08% 300
2017
Q2 		$27M Buy
587,000
+487,000
+487% +$23.6M 0.15% 185
2017
Q1 		$4.33M Buy
+100,000
New +$4.28M 0.02% 565
2015
Q3 		– Sell
-37,700
Closed -$1.8M – 863
2015
Q2 		$1.8M Sell
37,700
-195,500
-84% -$8.29M 0.01% 582
2015
Q1 		$9.26M Buy
+233,200
New +$8.34M 0.06% 344

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Point72 Asset Management's NBIX Position: Q2 2024 in Review

Point72 Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 837,426 shares — an estimated $115M sold.

Point72 Asset Management first reported a position in NBIX in Q1 2015 and held it in 22 quarters. The position peaked at $290M in Q3 2023. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Point72 Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Point72 Asset Management sold 837,426 Neurocrine Biosciences shares in Q2 2024, an estimated $115M.
  • Point72 Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 22 quarters.
  • Point72 Asset Management's Neurocrine Biosciences position peaked at $290M in Q3 2023.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.